Trial Profile
A Multi-center Study of the Discontinuation of Imatinib in Adult Patients With Ph+ CML in CP Who Have a Complete Molecular Response to Imatinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms KID
- 08 Dec 2020 Status changed from recruiting to completed.
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
- 10 Jan 2014 Planned End Date changed from 1 June 2012 to 1 June 2015 as per ClinicalTrials.gov record.